Core Viewpoint - The medical device sector is experiencing significant challenges, described as being in a state of "cardiac arrest," primarily due to the impact of GLP-1 weight-loss drugs and tariff-induced margin pressures [1][8]. Group 1: Market Performance - The iShares U.S. Medical Devices ETF (IHI) has shown a flat performance recently, indicating a lack of growth in the sector [1]. - The ETF's stock basket is currently valued at 30 times earnings, despite a decline in stock prices over the past year [3]. - There is a potential downside risk of over 20%, with projections suggesting a drop to $44 if current market pressures continue [4]. Group 2: Industry Challenges - The rise of GLP-1 weight-loss drugs is perceived as a major threat to traditional medical device markets, leading to concerns about reduced demand for procedures like knee replacements and heart valves [8][9]. - The medical device industry is heavily reliant on international supply chains, and recent U.S. tariffs on imports from China, Europe, and India are negatively impacting profit margins [10]. - Companies are facing increased costs for components while struggling to raise prices for hospitals, which are already operating on thin margins [10]. Group 3: Risk Assessment - The ROAR score for IHI has significantly declined from a peak of 80 to 20, indicating an above-average risk of major loss in the sector [5].